Literature DB >> 7298764

Determination of cytarabine and uracil arabinoside in human plasma and cerebrospinal fluid by high-performance liquid chromatography.

H Breithaupt, J Schick.   

Abstract

A high-performance liquid chromatographic method for the determination of the antineoplastic agent cytarabine and its main metabolite uracil arabinoside in human plasma and cerebrospinal fluid is described. Complete separation from endogenous constituents was achieved by isocratic reversed-phase chromatography using phosphate buffer (0.05 M, pH 7.0) as the eluent. The limit of detection was 50 ng/ml. Day-to-day coefficients of variation were below 10%. The applicability of this rapid, simple and specific method for pharmacokinetic studies and monitoring of therapy was demonstrated.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7298764     DOI: 10.1016/s0378-4347(00)80248-0

Source DB:  PubMed          Journal:  J Chromatogr


  6 in total

1.  Extremely prolonged continuous intraperitoneal infusion of cytosine arabinoside.

Authors:  S Kirmani; S Zimm; S M Cleary; J Mowry; S B Howell
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

Review 2.  Stability of solutions of antineoplastic agents during preparation and storage for in vitro assays. III. Antimetabolites, tubulin-binding agents, platinum drugs, amsacrine, L-asparaginase, interferons, steroids and other miscellaneous antitumor agents.

Authors:  A G Bosanquet
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

3.  Chemotherapy with cytosine arabinoside in a child with Burkitt's lymphoma on maintenance hemodialysis and hemofiltration.

Authors:  J M Pöschl; G Klaus; U Querfeld; R Ludwig; O Mehls
Journal:  Ann Hematol       Date:  1993-07       Impact factor: 3.673

4.  Exchange of cerebrospinal fluid in accidental intrathecal overdose of cytarabine.

Authors:  P Lafolie; J Liliemark; O Björk; J Aman; L Wranne; C Peterson
Journal:  Med Toxicol Adverse Drug Exp       Date:  1988 May-Jun

5.  Inhibition of fludarabine metabolism by arabinosylcytosine during therapy.

Authors:  A Kemena; V Gandhi; D S Shewach; M Keating; W Plunkett
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

6.  Validation of a Novel Potentiometric Method Based on a Polymeric PVC Membrane Sensor Integrated with Tailored Receptors for the Antileukemia Drug Cytarabine.

Authors:  Ayman H Kamel; Abd El-Galil E Amr; Nashwa H Ashmawy; Hoda R Galal; Abdulrahman A Almehizia; Teraze A Youssef; Mohamed A Al-Omar; Ahmed Y A Sayed
Journal:  Polymers (Basel)       Date:  2020-06-14       Impact factor: 4.329

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.